Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Angelalign TechnologyFRA:77D +2.94%75 3-Year EBITDA Growth Rate is 3.70% as of Jun. 2026, which is at its 10-year median of 3.70. GuruFocus rates FRA:77D with a GF Score™ of 75/100 and a GF Value™ of €11.73 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Angelalign Technology ranks worse than 58.28% on this metric.
During the past 12 months, Angelalign Technology's average EBITDA Per Share Growth Rate was 99.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 3.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -3.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Angelalign Technology was 62.90% per year. The lowest was -22.50% per year. And the median was 3.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Angelalign Technology 3-Year EBITDA Growth Rate Related Terms
FRA:77D vs ISRG, BDX, RMD: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Angelalign Technology's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Angelalign Technology 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Angelalign Technology's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Angelalign Technology's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 3.70% mean?
Angelalign Technology (FRA:77D) has a 3-Year EBITDA Growth Rate of 3.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Angelalign Technology and its competitors. This is near median its historical median of 3.70. According to the industry distribution chart, Angelalign Technology ranks #401 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 58.3%.
Is Angelalign Technology's 3-Year EBITDA Growth Rate too high?
Angelalign Technology's current 3-Year EBITDA Growth Rate of 3.70% is near median its 10-year median of 3.70. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.90. Angelalign Technology's value of 3.70% is 53.2% below this industry median. Based on the distribution chart, Angelalign Technology ranks #401 out of 688 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Angelalign Technology has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Angelalign Technology's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Angelalign Technology ranks #401 out of 688 companies for 3-Year EBITDA Growth Rate. This places Angelalign Technology in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.90. Angelalign Technology's value of 3.70% is 53.2% below this benchmark. While the company's 10-year median is 3.70 vs. the industry median of 7.90, Angelalign Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.90, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Angelalign Technology's current 3-Year EBITDA Growth Rate of 3.70% is 53.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Angelalign Technology and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Angelalign Technology's current 3-Year EBITDA Growth Rate is 3.70%, which is near median its own 10-year median of 3.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Angelalign Technology stock overvalued right now?
Based on GuruFocus' analysis, Angelalign Technology (FRA:77D) is currently considered Modestly Undervalued. The stock's GF Value™ is €11.73, compared to a current price of €10.50 — trading 10.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 3.70%, which is near median its 10-year median of 3.70 and 53.2% below the Medical Devices & Instruments industry median of 7.90. Angelalign Technology's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Angelalign Technology (FRA:77D), the current 3-Year EBITDA Growth Rate is 3.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Angelalign Technology (FRA:77D) Overvalued in 2026?
Based on GuruFocus' analysis, Angelalign Technology stock appears to be undervalued.
The current stock price of €10.50 is trading 10.5% below its estimated GF Value™ of €11.73.
GuruFocus considers Angelalign Technology to be Modestly Undervalued.
Key valuation signals for FRA:77D:
3-Year EBITDA Growth Rate: 3.70% (near median its 10-year median of 3.70)
GF Value™: €11.73 vs. price of €10.50 (10.5% below fair value)
Industry Position: 53.2% below the Medical Devices & Instruments median (#401 of 688)
No single metric tells the full story. See the FRA:77D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Angelalign Technology Inc is an investment holding company. It is principally engaged in clear aligner treatment solutions, including treatment planning services, manufacturing, and marketing of clear aligners. The company provides dental professionals with self-developed digital orthodontic solutions. The company's Angelalign clear aligner system facilitates dental professionals throughout the entire clear aligner treatment process, including digitally-assisted case assessment support and treatment planning services, provide dental professionals with digitally-assisted case assessment support and treatment planning services, and helps dental professionals design, review, and modify treatment plans.
75GF Score
Get the complete analysis for FRA:77D
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:77D has been successfully added to your 
